Chester County News and Community Website
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, imdusiran and AB-101, at the European Association for the Study of the …
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the acceptance of five abstracts, including a late-breaking study, for presentation at the European Association for the Study of the Liver …
Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its financial results for the fourth quarter and fiscal year 2024, alongside significant corporate updates. The biotechnology company reaffirmed its commitment …
Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced significant changes to its leadership team, naming Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski succeeds Michael J. McElhaugh, …
Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring Read More WARMINSTER, PA — Arbutus Biopharma Corporation (NASDAQ: ABUS) has unveiled its strategic objectives for 2025 alongside an encouraging financial update, emphasizing progress in its efforts to develop a functional cure for …
Arbutus Biopharma Sets Sights on Advancing HBV Cure in 2025 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced promising new data from its IM-PROVE I Phase 2a clinical trial, suggesting significant advancements in treatment for chronic hepatitis B …
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment Read More WARMINSTER, PA and OXFORD, United Kingdom — Arbutus Biopharma Corporation and Barinthus Biotherapeutics recently unveiled encouraging preliminary results from their Phase 2a IM-PROVE II clinical trial at the American Association …
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released its third-quarter 2024 financial results, showcasing significant progress in its clinical trials and a stable financial position. The company is …
Arbutus Biopharma Advances Clinical Trials and Strengthens Financial Position in Q3 2024 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its second quarter 2024 financial results and provided an update on its corporate strategy.
Arbutus Biopharma Reports Promising Data and Restructuring Plans in Q2 2024 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its plans to release its second quarter 2024 financial results and provide a corporate update on Thursday, August 1, 2024.
Arbutus Biopharma to Reveal Q2 Financials and Corporate Updates Read More